Publication date:
December 9, 2020
Paper calls for urgent action to combat global burden of CVD through prevention programs and access to emergency care, medications
WASHINGTON (Dec. 9, 2020) The number of people dying from cardiovascular disease (CVD) is steadily rising, including one-third of all deaths globally in 2019, according to a paper in the
Journal of the American College of Cardiology that reviewed the total magnitude of CVD burden and trends over 30 years around the world. The data reflects an urgent need for countries to establish cost-effective public health programs aimed at reducing cardiovascular risk through modifiable behaviors.
CVD, particularly ischemic heart disease and stroke, is the leading cause of death around the world and a huge contributor to disability and rising health care costs.
ACC/AHA Update Two Atrial Fibrillation Performance Measures
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Experts Push for New Cancer Drug Dosing Recommendations
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
CROs partner on women’s oncology clinical solutions Health Decisions and OncoBay Clinical will collaborate on specialized clinical development services addressing therapies for women’s cancers.
Health Decisions is a contract research organization (CRO) honed in on women’s health clinical research, and diagnostic and device development; OncoBayClinical tackles complex, early-phase oncology programs. Together, the two CROs will harness expertise in women’s health and oncology to bolster clinical programs for sponsors seeking novel treatment options in women’s cancers.
Patrick Phillips, Health Decisions CEO, told Outsourcing-Pharma that women historically are underrepresented in clinical research, even in trials investigating treatments specifically for women.